NCT07787156Recruiting
Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
This study will test a remote approach to help people who may be at higher risk for pancreatic cancer learn about and decide whether to get genetic testing and a blood test that looks for signs of several cancers (MCED testing). The study is focused on Black, Latino/a, and Medicaid-enrolled individuals who may have had less access to cancer genetics and early detection services. About 80 participants, who reside in Massachusetts, will be assigned by chance to receive either online education alone or online education plus a phone call with a trained educator from the Pancreatic Cancer Action Network (PanCAN). After the education, participants can choose whether or not to have genetic testing and/or MCED testing. The main goal is to learn whether this approach is practical to carry out, acceptable to participants, and delivered as planned. Participants will complete 3 surveys during study participation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 24 Aug 2026
- Start date
- 15 Oct 2026
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT07787156
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 15 Oct 2026 to the primary completion date, 30 Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior genetic testing related to PDAC genetic risk
Other illness
- Cancer diagnosis in the last 3 years (excluding non-melanoma skin cancers)
Age
- Less than age 50 years or age not within 10 years of the earliest PDAC diagnosis in their family
Other
- Currently pregnant
- Insurance other than Medicaid or race/ethnicity other than Black or Latino/a
- Genetic counseling in the last 3 years
- Living in a state other than Massachusetts
- Language other than English
- Three members of the same family already enrolled in the study
Who the study is looking for
- Aged 50 years or older OR 10 years younger than the earliest PDAC diagnosis in a family member
- Current Medicaid enrollment and/or Black and/or Latino/a
- Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if MCED screening test indicates possible malignancy
- Living in the state of Massachusetts
- No prior multi-gene panel genetic testing related to PDAC genetic risk
- Internet access to complete study surveys
- English speaking
- Willing to complete study surveys
- At least one first-degree relative with a PDAC diagnosis by participant report OR Any blood relative with a known pathogenic or likely pathogenic variant in a cancer susceptibility gene related to PDAC by participant report (e.g. ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, or TP53)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.